Diabetic Nephropathy Epidemiology

Diabetic Neuropathy Insights and Trends

• According to DelveInsight’s analysis, the total diagnosed prevalent cases of Diabetic Neuropathy were ~XXXX in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.

• Diabetic Neuropathy is most prevalent in the United States among the 7MM, driven by a high diabetes burden, aging population, sedentary lifestyle, and higher rates of obesity, all of which significantly increase the risk of nerve damage and disease progression.

• Patients with Diabetic Neuropathy often experience a higher disease burden with increasing age and longer duration of diabetes, with some studies suggesting a slightly higher prevalence in females. This disparity is largely driven by risk factors such as poor glycemic control, lifestyle patterns, and comorbidities, which contribute to progressive nerve damage and worsening symptoms over time.

• The rising global prevalence of diabetes, aging populations, sedentary lifestyles, and increasing prevalence of obesity are expected to sustain the burden of diabetic neuropathy over the next decade. Strengthening early screening, optimizing glycemic control, and improving access to effective pain management and disease-modifying therapies will be key determinants of future trends.

Diabetic Neuropathy Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Diabetic Neuropathy: ~XXXX

• 2036 Projected Diagnosed Prevalent Cases of Diabetic Neuropathy: XXXX

• Diabetic Neuropathy  Growth Rate (2026–2036): ~XX% CAGR

DelveInsight's ‘Diabetic Neuropathy Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Diabetic Neuropathy, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

Diabetic Neuropathy Understanding 

Diabetic Neuropathy Overview

Diabetic Neuropathy is a common microvascular complication of diabetes, occurring when prolonged hyperglycemia leads to nerve damage and impaired nerve signaling. It can range from mild to severe, with symptoms such as numbness, tingling, pain, and loss of sensation, particularly in the extremities, and may progress to significant functional impairment in advanced stages. The condition is primarily caused by chronic poor glycemic control, metabolic dysfunction, and vascular damage affecting nerve supply. 

Diabetic Neuropathy Diagnosis

Diabetic Neuropathy is diagnosed through clinical evaluation and neurological assessment, often identified during routine diabetes checkups. A detailed medical history and physical examination focusing on symptoms such as numbness, tingling, and pain are essential. Diagnostic tests include nerve conduction studies and electromyography to assess nerve function, along with quantitative sensory testing. Additional evaluations, such as monofilament testing, vibration perception, and autonomic function tests, help confirm the diagnosis and assess severity, while blood tests are performed to rule out other potential causes of neuropathy.

Further details are provided in the report.

Diabetic Neuropathy Epidemiology

Key Findings from Diabetic Neuropathy Epidemiological Analysis and Forecast 

• According to DelveInsight’s estimates, the US accounts for the highest prevalent cases in 2025 and is expected to increase at a significant CAGR by 2036.

• According to the International Diabetes Federation (IDF), more than 43 million adults in the United States are affected by diabetes, highlighting the substantial national disease burden and associated risk of long-term complications.

• According to secondary sources, diabetic neuropathy, a common complication of diabetes, affects more than 30% of individuals with the disease, as reported by the Survey Research Group of the Japan Physicians Association.

• The observed female predominance and earlier onset of Diabetic Neuropathy highlight the importance of sex-specific screening, early diagnosis, and timely intervention to prevent disease progression and long-term complications. 

• According to secondary sources, approximately 32% of individuals with diabetes in Italy were reported to have diabetic neuropathy, highlighting a substantial burden of neurological complications.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of Diabetic Neuropathy, explaining its causes, signs and symptoms, and pathogenesis.

• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Diabetic Neuropathy Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting

• 11-year Forecast 

• Patient Burden Trends (by geography)

Key Question

• What are the disease risks, burdens, and unmet needs of Diabetic Neuropathy? What will be the growth opportunities across the 7MM concerning the patient population with Diabetic Neuropathy?

• What is the historical and forecasted Diabetic Neuropathy patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.

• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.